Denali Therapeutics Inc. DNLI Option Fee Payment — Total collaboration revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s option fee payment — total collaboration revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s option fee payment — total collaboration revenue?
- Denali Therapeutics Inc. (DNLI) reported option fee payment — total collaboration revenue of $2.5M in Q4 2026.
- How has Denali Therapeutics Inc.'s option fee payment — total collaboration revenue changed year-over-year?
- Denali Therapeutics Inc.'s option fee payment — total collaboration revenue increased by 100.0% year-over-year, from $1.25M to $2.5M.
- What is the long-term trend for Denali Therapeutics Inc.'s option fee payment — total collaboration revenue?
- Over 3 years (2022 to 2026), Denali Therapeutics Inc.'s option fee payment — total collaboration revenue has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.
- What does option fee payment — total collaboration revenue mean?
- This metric represents the revenue recognized from option fees associated with collaborative research and development agreements. It reflects the financial value generated when partners exercise rights or pay for the privilege to access the company's proprietary technology platforms or specific therapeutic programs. This revenue stream is a key indicator of the commercial interest in the company's early-stage pipeline and the monetization of its intellectual property through strategic partnerships.